Related Experiment Video
Updated: Jul 4, 2025
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
422
Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An
Journal of Drugs in Dermatology : JDD
|February 2, 2024
Summary
The 40-gene expression profile (40-GEP) test offers crucial prognostic data for cutaneous squamous cell carcinoma (cSCC) beyond traditional staging. Incorporating this test into guidelines can improve patient outcomes by better predicting metastasis risk.
Area of Science:
- Dermatology
- Oncology
- Genomics
Background:
- Cutaneous squamous cell carcinoma (cSCC) incidence is rising.
- Current staging systems have limitations in predicting metastasis.
- Gene expression profile (GEP) testing offers a validated method for risk stratification.
Purpose of the Study:
- Review literature on GEP testing for cSCC prognosis.
- Develop consensus statements for clinical use.
- Guide dermatology clinicians on GEP test integration.
Main Methods:
- Comprehensive literature search (PubMed, EMBASE, Scopus).
- Expert panel review of 21 relevant articles.
- Modified Delphi process for consensus and SORT criteria for recommendations.
Main Results:
- 7 consensus statements and recommendations developed.
- 6 recommendations received a Strength of Recommendation (SORT) "A".
- 1 recommendation received a SORT "C".
Conclusions:
- 40-GEP test provides independent prognostic information beyond pathology.
- Integrating GEP testing into guidelines can refine metastasis risk assessment.
- Improved risk stratification may reduce cSCC morbidity and mortality.
